CVD Risk Reduction and Lipid Management: State of the Science in HDL Therapy

Credit Area For Credit: Register/Login     View Activity As Guest

Release Date: May 15, 2012          Expiration Date: May 15, 2013

This program has an associated Grand Rounds; Click Here for information.

Program Description

For patients with cardiovascular disease, one size does not fit all.

This new CME-certified webcourse – endorsed by the National Lipid Association – examines the importance of lipoprotein management for secondary prevention of major adverse cardiac events in post-ACS patients. Participants will learn to recognize residual risk associated with even intense statin therapy to lower LDL, as well as the limitations of current therapies to increase HDL, while building an awareness of the prospects of novel therapies to increase HDL and reduce CVD risk in ACS patients, as well as to provide primary prevention in high-risk patients.


Professor, Departments of Medicine, Epidemiology,
and Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, MD
Read Biography

Target Audience

This activity is intended for cardiologists and primary care physicians involved in the treatment of patients with dyslipidemia.

Educational Objectives

This activity was designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Examine the extent of residual CVD risk that continues to burden dyslipidemic ACS patients despite intensive statin treatment
  • Compare the relative effectiveness of existing treatments to raise HDL and reduce CVD risk
  • Explain the rationale for developing CETP modulators and inhibitors to increase HDL and reduce CVD risk
  • Discuss how the modulation of complex cholesterol metabolism could have an impact on atherogenesis and improve clinical outcomes


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     For questions regarding CME credit, the post-test, or evaluation, please email

Disclosure Statement

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:


Michael Miller, MD, FACC, FAHA: Consultant: Amarin, Abbott, Roche; Research: Abbott, Merck, Roche; Speaker: Merck


Robert S. Rosenson, MD, FACC, FACP, FAHA, FNLA: Advisory Board: Abbott, Amgen, AstraZeneca, LipoScience Inc., Sanofi-Aventis; Stock Holdings: LipoScience Inc.

Eliot A. Brinton, MD, FAHA, FNLA: Consultant: Abbott, Amarin, Daiichi-Sankyo, Essentialis, GlaxoSmithKline, Merck, Roche; Speaker: Abbott, Amarin, Daiichi-Sankyo, GlaxoSmithKline, Merck; Researcher: Abbott, Amarin, Merck; Scientific Advisory Board: Atherotech

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Barry Watkins, PhD; Bradley Pine; Blair St. Amand; Jay Katz, Dana Simpler, MD: Nothing to Disclose

FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

Instructions for Participants and Obtaining CME Credit

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hours. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.


This program is endorsed by the National Lipid Association
This activity is jointly sponsored by


Supported by an independent educational grant from Genentech

By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.